Postinflammatory hyperpigmentation - Hyperpigmentation Postinflammatory
Hyperpigmentation Postinflammatory (Postinflammatory hyperpigmentation) ose ma'i pa'u e fa'aalia i le fa'ateleina o le pa'u ile pa'u pe a mae'a le fula ole pa'u. hyperpigmentation postinflammatory (postinflammatory hyperpigmentation) e mafai ona mafua mai i le fa'aumiumi o le susulu o le la, fula, po'o isi manu'a o le pa'u, e aofia ai ma mea e feso'ota'i ma siama. O tagata e sili atu le pogisa o le paʻu o le paʻu e masani ona sili atu ona faʻafefe i le hyperpigmentation ma le tele o le la.
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
References
Postinflammatory hyperpigmentation (PIH) ose fa'afitauli masani o le pa'u e tupu pe a uma le pa'u po'o manu'a. E foliga e umi se taimi ma e sili atu ona leaga i tagata e pogisa pa'u (Fitzpatrick skin types III–VI) . E ui lava e masani ona lelei na o ia, e mafai ona umi se taimi, o lea e masani ona manaʻomia togafitiga mo se taimi umi. O le tu'ufa'atasia o togafitiga eseese e sili ona lelei.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
